Histologic scoring indices for evaluation of disease activity in ulcerative colitis.
暂无分享,去创建一个
B. Feagan | V. Jairath | R. Khanna | C. Parker | J. Macdonald | M. Mosli | S. Nelson | G. Zou | B. Levesque | K. A. Baker
[1] R. Kiesslich,et al. Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. , 2017, Gastrointestinal endoscopy.
[2] N. Khan,et al. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature , 2017, Current Treatment Options in Gastroenterology.
[3] S. Vermeire,et al. Tu1943 Validation of the Simplified Geboes Score for Ulcerative Colitis , 2016 .
[4] S. Osawa,et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. , 2016, Journal of Crohn's & colitis.
[5] J. Jung,et al. Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis , 2015, Gastroenterology research and practice.
[6] M. Silverberg,et al. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease , 2015, Inflammatory bowel diseases.
[7] S. Travis,et al. Endoscopic Disease Activity in Inflammatory Bowel Disease , 2015, Current Gastroenterology Reports.
[8] S. Ladelund,et al. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] L. Stitt,et al. Development and validation of a histological index for UC , 2015, Gut.
[10] S. Travis,et al. Development and validation of the Nancy histological index for UC , 2015, Gut.
[11] A. Wiernicka,et al. Histological healing after infliximab induction therapy in children with ulcerative colitis. , 2015, World journal of gastroenterology.
[12] G. delle Fave,et al. Application of clinical indexes in ulcerative colitis patients in regular follow-up visit: correlation with endoscopic 'mucosal healing' and implication for management. Preliminary results. , 2015, European Review for Medical and Pharmacological Sciences.
[13] K. Farkas,et al. Is mucosal healing more common than clinical remission in ulcerative colitis? – Is it the truth or only a myth coming from the studies? , 2015, Scandinavian journal of gastroenterology.
[14] Y. Kohgo,et al. Su1705 Quantification of Autofluorescence Imaging Is Useful for Objectively Assessing the Severity of Ulcerative Colitis , 2015 .
[15] T. Tomita,et al. Su1242 Serum Reg Iα Is a Marker to Predict Histological and Clinical Activity in Ulcerative Colitis , 2015 .
[16] M. Silverberg,et al. 593 Predictive Value of Basal Plasmacytosis on Clinical Relapse in Quiescent Ulcerative Colitis , 2015 .
[17] C. Taxonera,et al. Tu1113 Endoscopic and Histologic Remission Correlation With Biomarkers in UC Patients Treated With Adalimumab , 2015 .
[18] Christopher R. Cabanski,et al. Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis , 2015 .
[19] H. Ogata,et al. Su2031 Evaluation of Severity Using Endoscopic Dual Red Imaging Targeting Submucosal Vessel in Patients With Ulcerative Colitis , 2015 .
[20] S. Vermeire,et al. Su1212 A Simplified Histological Geboes Score for Ulcerative Colitis , 2015 .
[21] J. Langhorst,et al. Su1235 Monitoring of Histologically Defined Healing in Ulcerative Colitis: Performance of Fecal Lactoferrin, Calprotectin, PMN-Elastasis and CRP and WBC Compared to the Riley Score , 2015 .
[22] G. Kaplan,et al. Tu1219 Clinical Outcome of Ulcerative Colitis Patients With Complete Mucosal Healing but With Subtle Abnormalities Detected by Novel iSCAN Endoscopic , 2015 .
[23] F. Zerbib,et al. Tu1339 Mucosal and Histologic Response to Cyclosporin in Ulcerative Colitis: A Cohort Study , 2015 .
[24] G. Kaplan,et al. Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings , 2015, Endoscopy.
[25] A. Tursi,et al. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. , 2014, Clinics and research in hepatology and gastroenterology.
[26] A. Bitton,et al. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. , 2014, Journal of Crohn's & colitis.
[27] S. Vermeire,et al. Development of a Simplified histological Geboes Score for ulcerative colitis , 2015 .
[28] P. Siersema,et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. , 2015, Journal of Crohn's & Colitis.
[29] Rubin David,et al. O-001 Budesonide MMX® 9 mg for Inducing Remission in Patients With Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled With Oral 5-ASAs , 2014 .
[30] W. Hong,et al. P-102 Histologic Activity After Induction Therapy with Multimatrix Mesalamine Is Associated with 12-Month Remission Status in Ulcerative Colitis , 2014 .
[31] S. Travis,et al. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.
[32] F. Rizzello,et al. Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[33] Michael Joseph Peterson,et al. Reproducibility of histological assessments of disease activity in UC , 2014, Gut.
[34] T. Voiosu,et al. Evaluation of histologic features with potential prognostic value in ulcerative colitis. , 2014, Romanian journal of internal medicine = Revue roumaine de medecine interne.
[35] J. Salleron,et al. Comparing histological activity indexes in UC , 2014, Gut.
[36] G. D'Haens,et al. A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research , 2014, Inflammatory bowel diseases.
[37] Elizabeth R. Paine,et al. Colonoscopic evaluation in ulcerative colitis , 2014, Gastroenterology report.
[38] L. Stitt,et al. Sa1196 Responsiveness of Endoscopic Indices in the Evaluation of Ulcerative Colitis , 2014 .
[39] K. Chayama,et al. Tu1521 Correlation Between Endocytoscopy and Histopathological Activity in the Remission Stage of Ulcerative Colitis: a Pilot Study , 2014 .
[40] D. Rubin,et al. Sa1213 Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis , 2014 .
[41] C. Hassan,et al. Second-generation colon capsule endoscopy vs. colonoscopy in pediatric ulcerative colitis: a pilot study , 2014, Endoscopy.
[42] L. Stitt,et al. P150 Responsiveness of endoscopic indices in the evaluation of ulcerative colitis , 2014 .
[43] M. Peterson,et al. P284 Agreement of central readers in the evaluation of histopathological disease activity in ulcerative colitis , 2014 .
[44] F. Rizzello,et al. P452 Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program , 2014 .
[45] A. Wiernicka,et al. P440 Influence of induction therapy with infliximab on histological changes in children with ulcerative colitis – preliminary data , 2014 .
[46] W. Sandborn,et al. Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis , 2014, Inflammatory bowel diseases.
[47] E. Markova,et al. EVALUATION OF HISTOLOGICAL PARAMETERS IN PATIENTS WITH CLINICAL REMISSION OF ULCERATIVE COLITIS , 2014 .
[48] D. Rubin,et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[49] D. Altman,et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. , 2013, Gastroenterology.
[50] A. Cheifetz,et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[51] P. Rutgeerts,et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.
[52] P. Rutgeerts,et al. Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis , 2013, Inflammatory bowel diseases.
[53] W. Sandborn,et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study , 2013, Gut.
[54] S. Robson,et al. Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission , 2013, Inflammatory bowel diseases.
[55] G. Kaplan,et al. P112 iSCAN-High definition colonoscopy correlates with white light endoscopy and histology assessment in mucosal healing for ulcerative colitis , 2013 .
[56] A. Zinsmeister,et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[57] H. Miwa,et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis , 2012, Journal of gastroenterology and hepatology.
[58] M. Neurath,et al. Ulcerative colitis: UCCIS—a reproducible tool to assess mucosal healing , 2012, Nature Reviews Gastroenterology &Hepatology.
[59] D. Rubin,et al. Correlation Between Clinical, Endoscopic, and Histologic Disease Activity in Ulcerative Colitis: 1712 , 2012 .
[60] A. Gasbarrini,et al. Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases. , 2012, World journal of gastroenterology.
[61] F. Rizzello,et al. OC.12.1 INTEROBSERVER AGREEMENT IN IBD SCORES REQUIRES EXPERTISE AND EDUCATION: PRELIMINARY RESULTS FROM AN ONGOING IG-IBD STUDY , 2012 .
[62] E. Kuipers,et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation , 2011, Inflammatory bowel diseases.
[63] B. Sands,et al. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? , 2011, Inflammatory bowel diseases.
[64] E. Jung,et al. Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis , 2012, International Journal of Colorectal Disease.
[65] R. Kiesslich,et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease , 2011, Gut.
[66] L. Kupčinskas,et al. Randomised clinical trial: the efficacy and safety of propionyl‐l‐carnitine therapy in patients with ulcerative colitis receiving stable oral treatment , 2011, Alimentary pharmacology & therapeutics.
[67] D. Altman,et al. Translational Gastroenterology , 2011 .
[68] G. Porro,et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[69] H. Ogata,et al. In Vivo Visualization and Evaluation of Colorectal Inflammation in Ulcerative Colitis by a Newly Integrated Endocytoscopy , 2011 .
[70] Jun Kato,et al. Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients? , 2011, Journal of gastroenterology and hepatology.
[71] S. Travis,et al. Depth of remission may not predict outcome of UC over 2 years , 2011, Gut.
[72] E. Szigethy,et al. Inflammatory bowel disease. , 2011, Pediatric clinics of North America.
[73] F. Nagy,et al. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. , 2010, Journal of Crohn's & colitis.
[74] C. Brensinger,et al. M1227 Which Endoscopic or Clinical Factor is Most Predictive of Future Disease Course in Patients With Ulcerative Colitis , 2010 .
[75] H. Ogata,et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients , 2010, Journal of Gastroenterology.
[76] T. Ohkusa,et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: Inter‐ and intraobserver consistency , 2010, Inflammatory bowel diseases.
[77] G. Gasbarrini,et al. Clinical trial: oral colon‐release parnaparin sodium tablets (CB‐01‐05 MMX®) for active left‐sided ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.
[78] T. Matsui,et al. VALIDITY OF ACTIVITY INDICES IN ULCERATIVE COLITIS: COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES , 2010, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[79] L. Peyrin-Biroulet,et al. Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.
[80] P. Renzulli,et al. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes , 2009, Inflammatory bowel diseases.
[81] S. Cucchiara,et al. PA29 EFFECTIVENESS OF A RECTAL INFUSION OF LACTOBACILLUS REUTERI ATCC 55730 IN CHILDREN WITH DISTAL ACTIVE ULCERATIVE COLITIS , 2009 .
[82] D. Altman,et al. 1049 Identification of Items to Be Included in An Ulcerative Colitis Endoscopic Index of Severity (UCEIS) , 2009 .
[83] D. Altman,et al. WHICH ACTIVITY INDEX FOR ULCERATIVE COLITIS? EVALUATION OF INTER-OBSERVER VARIATION IN CLINICAL, ENDOSCOPIC AND COMPOSITE INDICES , 2009 .
[84] D. Altman,et al. W1205 How Variable Is the Mayo Score Between Observers and Might This Affect Trial Recruitment or Outcome , 2009 .
[85] A. Ensari,et al. Quantitative endoscopic and histologic activity assessment of ulcerative colitis. , 2009, Acta gastro-enterologica Belgica.
[86] D. Altman,et al. P086 - Which activity index for ulcerative colitis (UC)? Evaluation of inter-observer variation in clinical, endoscopic and composite indices , 2009 .
[87] D. Altman,et al. P151 - How variable is the Mayo score between observers and might this affect trial recruitment or outcome? , 2009 .
[88] N. Harpaz,et al. Severity of Inflammation as a Predictor of Colectomy in Patients With Chronic Ulcerative Colitis , 2009, Diseases of the colon and rectum.
[89] B. Warren,et al. HOW MUCH AGREEMENT IS THERE BETWEEN HISTOLOGICAL, ENDOSCOPIC AND CLINICAL ASSESSMENTS OF REMISSION IN ULCERATIVE COLITIS? , 2009 .
[90] T. Ohkusa,et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis , 2008, Journal of gastroenterology and hepatology.
[91] I. Gorelov,et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.
[92] Tong Lu,et al. Are endoscopic grading and scoring systems in inflammatory bowel disease the same? , 2008, Saudi medical journal.
[93] A. Staiano,et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[94] Q. Ouyang,et al. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. , 2008, World Journal of Gastroenterology.
[95] N. Harpaz,et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.
[96] R. Petras,et al. Pathology of inflammatory bowel disease. , 2007, Seminars in pediatric surgery.
[97] M. Vatn,et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.
[98] D. Altman,et al. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation , 2007, Trials.
[99] W. Sandborn,et al. Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.
[100] Philippe Marteau,et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.
[101] O. Maeda,et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis , 2006, Gut.
[102] T. Ohkusa,et al. CURRENT OPINION OF ACTIVITY INDEX FOR COLONOSCOPIC AND HISTOLOGICAL FINDINGS IN ULCERATIVE COLITIS :A PROPOSAL OF NEW ACTIVITY ASSESSMENT BY CUMULATIVE METHOD OF SEVEN POINTS SCORES , 2006 .
[103] C. Hawkey,et al. Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.
[104] A. Cohen,et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.
[105] M. Schwartz,et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.
[106] P. Xie,et al. Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. , 2005, World journal of gastroenterology.
[107] O. Maeda,et al. Predictors of a response to cyclosporine or leukocyte removal therapy in patients with refractory ulcerative colitis , 2005 .
[108] M. Schwartz,et al. Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.
[109] T. Ohkusa,et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: A randomized, controlled pilot trial with long-term follow-up , 2005, Scandinavian journal of gastroenterology.
[110] L. Camellini,et al. Proposal of a New Clinical Index Predictive of Endoscopic Severity in Ulcerative Colitis , 2001, Digestive Diseases and Sciences.
[111] Anne Lavergne,et al. Colonoscopy of acute colitis , 1994, Digestive Diseases and Sciences.
[112] N. Greenberger,et al. Proctocolitis unresponsive to conventional therapy , 1987, Digestive Diseases and Sciences.
[113] D. W. Day,et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis , 1982, Digestive Diseases and Sciences.
[114] B. Korelitz,et al. Responses to drug therapy in ulcerative colitis , 1976, The American Journal of Digestive Diseases.
[115] G. Zou. Quantifying responsiveness of quality of life measures without an external criterion , 2005, Quality of Life Research.
[116] A. Imaoka,et al. Randomized placebo‐controlled trial assessing the effect of bifidobacteria‐fermented milk on active ulcerative colitis , 2004, Alimentary pharmacology & therapeutics.
[117] L. Mortelmans,et al. Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with 99mTc-HMPAO white blood cell scintigraphy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[118] L. Aabakken,et al. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis , 2004, BMC gastroenterology.
[119] S. Hanauer. Medical therapy for ulcerative colitis 2004. , 2004, Gastroenterology.
[120] D. Jewell,et al. Randomized, double‐blind, placebo‐controlled trial of oral aloe vera gel for active ulcerative colitis , 2004, Alimentary pharmacology & therapeutics.
[121] Alastair Forbes,et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.
[122] Z. Halpern,et al. Low-Dose Low-Molecular Weight Heparin (Enoxaparin) Is Effective as Adjuvant Treatment in Active Ulcerative Colitis: An Open Trial , 2001, Digestive Diseases and Sciences.
[123] G. Mazzacca,et al. Serum Transglutaminase Correlates with Endoscopic and Histopathologic Grading in Patients with Ulcerative Colitis , 2001, Digestive Diseases and Sciences.
[124] N. Harpaz,et al. Histological grading of disease activity in chronic IBD Inter- and intra-observer variation among pathologists with different levels of experience , 2003 .
[125] F. Manguso,et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double‐blind placebo‐controlled study , 2002, Alimentary pharmacology & therapeutics.
[126] D. Levine,et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.
[127] S. Friis,et al. Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1) , 2002, European journal of gastroenterology & hepatology.
[128] R. Löfberg,et al. Effect of Budesonide Enema on Remission and Relapse Rate in Distal Ulcerative Colitis and Proctitis , 2002, Scandinavian journal of gastroenterology.
[129] R. Cohen. Evolving medical therapies for ulcerative colitis , 2001, Current gastroenterology reports.
[130] M. Stolte,et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.
[131] S. Bunn,et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. , 2001, Journal of pediatric gastroenterology and nutrition.
[132] P. Munkholm,et al. An open-labeled, randomized study comparing systemic interferon-α-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis , 2001, American Journal of Gastroenterology.
[133] L. Mortelmans,et al. Tc-99m HMPAO White Blood Cell Scintigraphy in the Assessment of the Extent and Severity of an Acute Exacerbation of Ulcerative Colitis , 2001, Clinical nuclear medicine.
[134] A. Öst,et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.
[135] A. Sinha,et al. A gradual dose reduction is needed after 2 weeks of oral prednisolone treatment for ulcerative colitis , 2000 .
[136] Ardizzone,et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? , 1999, Alimentary pharmacology & therapeutics.
[137] R. Pounder,et al. A simple clinical colitis activity index , 1998, Gut.
[138] G. Porro,et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial , 1998, American Journal of Gastroenterology.
[139] Orlando,et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis , 1998, Alimentary pharmacology & therapeutics.
[140] P. Gionchetti,et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.
[141] T. Matsumoto,et al. Application of magnifying chromoscopy for the assessment of severity in patients with mild to moderate ulcerative colitis. , 1997, Gastrointestinal endoscopy.
[142] C. Feyerabend,et al. Nicotine enemas for active ulcerative colitis—a pilot study , 1997, Alimentary pharmacology & therapeutics.
[143] K. Batts,et al. Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis , 1997, Annals of Internal Medicine.
[144] G. Porro,et al. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single‐blind comparative study , 1996, Alimentary pharmacology & therapeutics.
[145] J. Walker-Smith,et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. , 1996, Journal of pediatric gastroenterology and nutrition.
[146] D. Kelleher,et al. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. , 1996, Gut.
[147] R. Modigliani,et al. Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.
[148] T. Bayless,et al. Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis , 1995 .
[149] L. Påhlman,et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis , 1994, Alimentary pharmacology & therapeutics.
[150] R. Odze,et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. , 1993, The American journal of surgical pathology.
[151] S. Hanauer,et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.
[152] K. Batts,et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. , 1993, The American journal of gastroenterology.
[153] L. Franzén,et al. Do technetium-99m hexamethylpropylene amine oxime-labeled leukocytes truly reflect the mucosal inflammation in patients with ulcerative colitis? , 1992, Scandinavian journal of gastroenterology.
[154] P. Munkholm,et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.
[155] T. Yao,et al. An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.
[156] T. Kirchner,et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. , 1992, Gastroenterology.
[157] Jacob Cohen,et al. A power primer. , 1992, Psychological bulletin.
[158] R A Deyo,et al. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. , 1991, Controlled clinical trials.
[159] S. Riley,et al. Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.
[160] Ami,et al. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.
[161] S. Riley,et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.
[162] C. H. Mason,et al. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Scandinavian journal of gastroenterology. Supplement.
[163] U. von Gaisberg,et al. [Ulcerative colitis. Activity index for the clinical and histological classification of inflammatory activity]. , 1988, Schweizerische medizinische Wochenschrift.
[164] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[165] L. Sutherland,et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.
[166] R. Willén,et al. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.
[167] G. Guyatt,et al. Measuring change over time: assessing the usefulness of evaluative instruments. , 1987, Journal of chronic diseases.
[168] Å. Danielsson,et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.
[169] H. Demonaco,et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. , 1986, The American journal of gastroenterology.
[170] M. Camilleri,et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. , 1986, Gastroenterology.
[171] C. Smith,et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.
[172] K. Geisinger,et al. Correlation of histopathologic evidence of disease activity with the presence of immunoglobulin-containing cells in the colons of patients with inflammatory bowel disease. , 1984, Human pathology.
[173] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[174] V. Binder,et al. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. , 1970, Scandinavian journal of gastroenterology.
[175] J. Goligher,et al. Sigmoidoscopy and cytology in the detection of microscopic disease of the rectal mucosa in ulcerative colitis , 1966, Gut.
[176] R. Carpenter,et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis , 1964, Gut.
[177] J. H. Baron,et al. Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.
[178] Matts Sg,et al. THE VALUE OF RECTAL BIOPSY IN THE DIAGNOSIS OF ULCERATIVE COLITIS1 , 1961 .
[179] S. Truelove,et al. Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.
[180] S. Truelove,et al. Cortisone in Ulcerative Colitis , 1954 .